December 15, 9:15 - 10:15

Title of Symposium

  • Role of Tumor Treatment Fields (TTFields) in the Management of Recurrent Ovarian Cancer



  • Waleed Shalaby, MD PhD, Senior Medical Director, NOVOCURE


Objectives for Symposium

  • What are TTFields and the mechanism of action (MOA)?
  • Review clinical data in recurrent ovarian cancer (ROC)
  • Present ongoing Phase 3 registration trial in ROC (ENGOT-ov50/INNOVATE-3 study )
  • Engage a panel discussion on the future role of TTFields in ovarian cancer


Agenda and Speakers (Tentative)

  • Who is NOVOCURE?

Ely Benaim, MD (~3-5 min), Chief Medical Officer, NOVOCURE

  • What are TTFields?

Moshe Giladi, PhD (~10 min), Dir. Preclinical Research, NOVOCURE

  • INNOVATE Pilot Study in ROC

Prof. Ignace Vergote, MD PhD (~10 min), Catholic University of Leuven, Belgium

  • ENGOT-ov50/INNOVATE-3 study Trial in ROC

Prof. David O’Malley MD (~10 min), Ohio State University, Columbus Ohio, USA

  • Panel Discussion – Current and Future Opportunities (~30 min)

Prof. Ignace Vergote, MD PhD (moderator)


Invited Panel Member

  • Prof. David O’Malley MD
  • Prof. Nicoletta Colombo MD PhD, European Institute of Oncology, Milan, Italy
  • Vanda Salutari, MD, Policlinico Agostino Gemelli of Rome, Italy
  • Prof. Bradley Monk, MD, FACOG, FACS, University of Arizona College of Medicine, Phoenix AZ, USA
  • Moshe Giladi PhD
  • Uri Weinberg, MD PhD, VP Clinical Development, NOVOCURE